Avirmax Biopharma Advances Groundbreaking Gene Therapy
Avirmax Biopharma, Inc., a pioneering company in the field of AAV gene therapies, has announced the start of Investigational New Drug (IND)-enabling studies for ABI-201. This innovative therapy seeks to address the critical health issue of Dry Age-related Macular Degeneration (AMD). With ABI-201, the company aims to revolutionize treatment options for this debilitating condition.
The Importance of ABI-201
ABI-201 is designed as a first-in-class AAV vector that efficiently delivers three distinct genes, targeting the root issues related to the dysregulation of complement activation and anti-inflammation. The goal here is to safeguard the retinal pigment epithelia and photoreceptors while blocking the progression to more severe retinal neovascularization. After just one intravitreal injection, ABI-201 aims to ensure lasting expression of these therapeutic genes, ultimately preserving vision and preventing retinal pathogenesis.
Understanding Age-related Macular Degeneration
AMD stands as the leading cause of irreversible blindness globally, particularly impacting individuals over 50 years old. With over 200 million cases reported, Dry AMD constitutes around 90% of instances. Unfortunately, current treatment options remain limited or ineffective, showcasing a significant gap in the healthcare landscape. This is where ABI-201 steps in with the potential to meet this urgent medical need.
Innovative Delivery Method Using AAV.N54
At the core of ABI-201’s design is Avirmax Biopharma's proprietary AAV.N54 capsid, recognized for its ability to deliver macula-targeted gene expression via intravitreal injection. Notably, AAV.N54 is also utilized in a different trial, ABI-110, that targets wet AMD, further emphasizing the versatility and effectiveness of Avirmax’s technology.
Ongoing Research and Future Plans
The current studies are focused on assessing ABI-201's safety and tolerability. There is a meticulous evaluation of vector biodistribution, transgene expression, and pharmacokinetics conducted on monkeys. This data will be critical for the next phases of development.
Plans are in place for Avirmax Biopharma to submit an IND application for ABI-201 by the end of 2025. Should they receive the necessary regulatory approval, the company is poised to commence Phase 1/2a clinical trials shortly thereafter, taking a confident step forward in expanding treatment options for patients suffering from Dry AMD.
A Bright Future for Gene Therapy
With its commitment to innovation, Avirmax Biopharma is dedicated to advancing gene therapy for retinal diseases. Exploring the capabilities of gene therapy not only provides hope for patients but also strengthens the biopharmaceutical landscape. The journey towards breaking new ground in treating debilitating eye conditions is a mission that Avirmax is passionately pursuing.
Frequently Asked Questions
What is ABI-201?
ABI-201 is a gene therapy developed by Avirmax Biopharma aimed at treating Dry Age-related Macular Degeneration.
Why is Dry AMD significant?
Dry AMD is the leading cause of irreversible blindness in individuals over 50, affecting millions worldwide.
How does ABI-201 work?
ABI-201 functions by delivering three genes that target inflammation and prevent retinal damage after a single injection.
What is the status of ABI-201?
Avirmax is currently conducting IND-enabling studies to understand ABI-201’s safety and efficacy before initiating clinical trials.
What is AAV.N54?
AAV.N54 is a proprietary capsid engineered by Avirmax to ensure effective gene delivery to the retina, utilized in both ABI-201 and ABI-110 therapies.
